Cargando…

Adoptive Cellular Immunotherapy in Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis

PURPOSE: Metastatic renal cell carcinoma (mRCC), as one of the most immunogenic tumors has been the focus of adoptive cellular immunotherapy (ACI), but the effects of ACI on objective response and survival in patients with mRCC are still controversial. Therefore, a systematic review and meta-analysi...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Xiaoyi, Liu, Ting, Zang, Xuefeng, Liu, Hao, Wang, Danhong, Chen, Hu, Zhang, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3647060/
https://www.ncbi.nlm.nih.gov/pubmed/23667530
http://dx.doi.org/10.1371/journal.pone.0062847
_version_ 1782268678125912064
author Tang, Xiaoyi
Liu, Ting
Zang, Xuefeng
Liu, Hao
Wang, Danhong
Chen, Hu
Zhang, Bin
author_facet Tang, Xiaoyi
Liu, Ting
Zang, Xuefeng
Liu, Hao
Wang, Danhong
Chen, Hu
Zhang, Bin
author_sort Tang, Xiaoyi
collection PubMed
description PURPOSE: Metastatic renal cell carcinoma (mRCC), as one of the most immunogenic tumors has been the focus of adoptive cellular immunotherapy (ACI), but the effects of ACI on objective response and survival in patients with mRCC are still controversial. Therefore, a systematic review and meta-analysis was performed to address this issue. METHODS: A search was conducted in the PubMed database for randomized clinical trials (RCTs) with ACI in mRCC. All included articles in this study were assessed according to the selection criteria and were divided into two groups: ACI versus no ACI. Outcomes were toxicity, objective response, 1-, 3- and 5-year survival. Risk ratio (RR) and 95% confidence intervals (CI) were calculated using a fixed-effects meta-analysis. Heterogeneity was measured by value of I(2) or P. RESULTS: 4 studies (469 patients) were included. Most of ACI-related adverse reactions were grade 1 or 2 and reversible. ACI provided significant benefit in terms of objective response (RR = 1.65; 95% CI, 1.15 to 2.38; P = 0.007, I(2) = 49%), 1-year survival (RR = 1.30; 95% CI, 1.12 to 1.52; P = 0.0008, I(2) = 0%), 3-year survival (RR = 2.76; 95% CI, 1.85 to 4.14; P<0.00001, I(2) = 46%) and 5-year survival (RR = 2.42; 95% CI, 1.21 to 4.83; P = 0.01, I(2) = 28%). CONCLUSIONS: ACI may be a safe and effective treatment for improving objective response, 1-, 3- and 5-year survival in patients with mRCC. Besides, five obstacles for ACI, including high degree of personalization, unsuitable WHO/RECIST response criteria, inadequate identification of tumor-associated antigens (TAAs), lack of effective combination treatments and less attention paid to the quality of ACI products, should be overcome during the successful development of more potent ACI for cancer in the future.
format Online
Article
Text
id pubmed-3647060
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-36470602013-05-10 Adoptive Cellular Immunotherapy in Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis Tang, Xiaoyi Liu, Ting Zang, Xuefeng Liu, Hao Wang, Danhong Chen, Hu Zhang, Bin PLoS One Research Article PURPOSE: Metastatic renal cell carcinoma (mRCC), as one of the most immunogenic tumors has been the focus of adoptive cellular immunotherapy (ACI), but the effects of ACI on objective response and survival in patients with mRCC are still controversial. Therefore, a systematic review and meta-analysis was performed to address this issue. METHODS: A search was conducted in the PubMed database for randomized clinical trials (RCTs) with ACI in mRCC. All included articles in this study were assessed according to the selection criteria and were divided into two groups: ACI versus no ACI. Outcomes were toxicity, objective response, 1-, 3- and 5-year survival. Risk ratio (RR) and 95% confidence intervals (CI) were calculated using a fixed-effects meta-analysis. Heterogeneity was measured by value of I(2) or P. RESULTS: 4 studies (469 patients) were included. Most of ACI-related adverse reactions were grade 1 or 2 and reversible. ACI provided significant benefit in terms of objective response (RR = 1.65; 95% CI, 1.15 to 2.38; P = 0.007, I(2) = 49%), 1-year survival (RR = 1.30; 95% CI, 1.12 to 1.52; P = 0.0008, I(2) = 0%), 3-year survival (RR = 2.76; 95% CI, 1.85 to 4.14; P<0.00001, I(2) = 46%) and 5-year survival (RR = 2.42; 95% CI, 1.21 to 4.83; P = 0.01, I(2) = 28%). CONCLUSIONS: ACI may be a safe and effective treatment for improving objective response, 1-, 3- and 5-year survival in patients with mRCC. Besides, five obstacles for ACI, including high degree of personalization, unsuitable WHO/RECIST response criteria, inadequate identification of tumor-associated antigens (TAAs), lack of effective combination treatments and less attention paid to the quality of ACI products, should be overcome during the successful development of more potent ACI for cancer in the future. Public Library of Science 2013-05-07 /pmc/articles/PMC3647060/ /pubmed/23667530 http://dx.doi.org/10.1371/journal.pone.0062847 Text en © 2013 Tang et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Tang, Xiaoyi
Liu, Ting
Zang, Xuefeng
Liu, Hao
Wang, Danhong
Chen, Hu
Zhang, Bin
Adoptive Cellular Immunotherapy in Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis
title Adoptive Cellular Immunotherapy in Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis
title_full Adoptive Cellular Immunotherapy in Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis
title_fullStr Adoptive Cellular Immunotherapy in Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis
title_full_unstemmed Adoptive Cellular Immunotherapy in Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis
title_short Adoptive Cellular Immunotherapy in Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis
title_sort adoptive cellular immunotherapy in metastatic renal cell carcinoma: a systematic review and meta-analysis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3647060/
https://www.ncbi.nlm.nih.gov/pubmed/23667530
http://dx.doi.org/10.1371/journal.pone.0062847
work_keys_str_mv AT tangxiaoyi adoptivecellularimmunotherapyinmetastaticrenalcellcarcinomaasystematicreviewandmetaanalysis
AT liuting adoptivecellularimmunotherapyinmetastaticrenalcellcarcinomaasystematicreviewandmetaanalysis
AT zangxuefeng adoptivecellularimmunotherapyinmetastaticrenalcellcarcinomaasystematicreviewandmetaanalysis
AT liuhao adoptivecellularimmunotherapyinmetastaticrenalcellcarcinomaasystematicreviewandmetaanalysis
AT wangdanhong adoptivecellularimmunotherapyinmetastaticrenalcellcarcinomaasystematicreviewandmetaanalysis
AT chenhu adoptivecellularimmunotherapyinmetastaticrenalcellcarcinomaasystematicreviewandmetaanalysis
AT zhangbin adoptivecellularimmunotherapyinmetastaticrenalcellcarcinomaasystematicreviewandmetaanalysis